Prioritizing Development Programs that Align with Fundraising Catalysts

Albert Kim is an accomplished physician-scientist with over two decades of professional experience in cardiovascular disease, novel therapeutic product development, translational science, and clinical medicine. He currently leads global clinical development efforts as Chief Medical Officer of Imbria Pharmaceuticals, whose mission is to advance transformative cardiovascular therapeutics by targeting cardiac energy metabolism.Prior to Imbria, Dr. Kim was most recently a Venture Partner at RA Ventures (Raven) and President and Chief Medical Officer of the Raven Blackbird Development Team. He also previously served as Chief Medical Officer at Cytel and held senior leadership roles at Novartis and Pfizer across early and late clinical development programs. At Pfizer, he served as Vice President, Clinical Research Head for the Internal Medicine Research Unit overseeing clinical research efforts for the legacy neuroscience portfolio and cardiometabolic diseases including NASH, diabetes, obesity, heart failure, and cachexia.Earlier in his career, Dr. Kim worked at the United States Food and Drug Administration’s Division of Cardiac Devices as a medical reviewer and held academic appointments in the VA Boston Cardiac Electrophysiology Section, at Boston University, and Harvard Medical School. He is a Fellow of the American College of Cardiology and the Heart Rhythm Society. Dr. Kim earned his undergraduate degree in biomedical engineering from Harvard University, his MD and PhD from the University of California, Los Angeles, and trained at Brigham and Women’s Hospital, Massachusetts General Hospital, and the University of California, San Francisco.

In April 2022, Mustafa Noor, MD, FACP joined Olatec’s Drug Development Team as Chief Medical Officer. At both large and small pharma companies, Dr Noor has contributed to numerous clinical drug development programs, leading and collaborating with teams in the development of novel therapeutics for inflammation, cardiometabolism, lipid and endocrine disorders as well as rare diseases. From 2001 to 2006, as medical director at Bristol-Myers Squibb, Dr Noor held positions of increasing responsibility in metabolic, cardiovascular, and antiviral programs. From 2006 to 2014 at GSK and at Pfizer he served as vice president and clinical head for GSK’s Center of Excellence in External Drug Discovery and for Pfizer’s Centers for Therapeutic Innovation focusing on open innovation, translational research and collaboration with biotech and academic partners on a portfolio of early-stage programs in indications for inflammatory diseases, including inflammatory bowel disease, rheumatoid arthritis, lupus and sarcoidosis. For the last several years Dr Noor has been a consultant CMO to emerging companies in the Boston/Cambridge area. Dr Noor completed his medical training at the University of Chicago and fellowship training in Endocrinology and Metabolism at the University of California, San Francisco. He holds a Master of Science in Clinical Investigation from Vanderbilt University and is a board-certified Internal Medicine specialist in Endocrinology and Metabolism.

Bernard Ravina is an Entrepreneur In Residence at Atlas Venture with over 20 years of drug development experience in government, academia, and industry. Most recently he was CMO of Praxis Precision Medicines. Prior to that he served as CMO of Voyager Therapeutics and worked in clinical development at Biogen. Dr Ravina holds an MD from the Johns Hopkins University School of Medicine and a Master’s in Clinical Epidemiology and Biostatistics from the University of Pennsylvania, where he completed training in neurology. After training, Dr Ravina held positions at NINDS/NIH in neurogenetics and at the University of Rochester School of Medicine where he was Associate Professor of Neurology and Director of the Movement and Inherited Neurological Disorders Unit.